Cargando…
Alendronate reduces periosteal microperfusion in vivo
OBJECTIVES: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate alendronate-induced microcirculatory reaction...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481298/ https://www.ncbi.nlm.nih.gov/pubmed/37681156 http://dx.doi.org/10.1016/j.heliyon.2023.e19468 |
_version_ | 1785101947270856704 |
---|---|
author | Kundert, Danielle N. Tavassol, Frank Kampmann, Andreas Gellrich, Nils-Claudius Lindhorst, Daniel Precht, Marc M. Schumann, Paul |
author_facet | Kundert, Danielle N. Tavassol, Frank Kampmann, Andreas Gellrich, Nils-Claudius Lindhorst, Daniel Precht, Marc M. Schumann, Paul |
author_sort | Kundert, Danielle N. |
collection | PubMed |
description | OBJECTIVES: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate alendronate-induced microcirculatory reactions in the calvarial periosteum of rats. STUDY DESIGN: Bone chambers were implanted into 48 Lewis rats. Microhemodynamics, inflammatory parameters, functional capillary density and defect healing were examined after alendronate treatment for two and six weeks using repetitive intravital fluorescence microscopy for two weeks. RESULTS: Microhemodynamics remained unchanged. In alendronate-treated rats, inflammation was slightly increased, functional capillary density was significantly reduced (day 10: controls 100.45 ± 5.38 cm/cm(2), two weeks alendronate treatment 44.77 ± 3.55 cm/cm(2), six weeks alendronate treatment 27.54 ± 2.23 cm/cm(2)) and defect healing was decelerated. The changes in functional capillary density and defect healing were dose-dependent. CONCLUSION: The bisphosphonate alendronate has a significant negative impact on periosteal microperfusion in vivo. This could be a promising target for the treatment of MRONJ. |
format | Online Article Text |
id | pubmed-10481298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104812982023-09-07 Alendronate reduces periosteal microperfusion in vivo Kundert, Danielle N. Tavassol, Frank Kampmann, Andreas Gellrich, Nils-Claudius Lindhorst, Daniel Precht, Marc M. Schumann, Paul Heliyon Research Article OBJECTIVES: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate alendronate-induced microcirculatory reactions in the calvarial periosteum of rats. STUDY DESIGN: Bone chambers were implanted into 48 Lewis rats. Microhemodynamics, inflammatory parameters, functional capillary density and defect healing were examined after alendronate treatment for two and six weeks using repetitive intravital fluorescence microscopy for two weeks. RESULTS: Microhemodynamics remained unchanged. In alendronate-treated rats, inflammation was slightly increased, functional capillary density was significantly reduced (day 10: controls 100.45 ± 5.38 cm/cm(2), two weeks alendronate treatment 44.77 ± 3.55 cm/cm(2), six weeks alendronate treatment 27.54 ± 2.23 cm/cm(2)) and defect healing was decelerated. The changes in functional capillary density and defect healing were dose-dependent. CONCLUSION: The bisphosphonate alendronate has a significant negative impact on periosteal microperfusion in vivo. This could be a promising target for the treatment of MRONJ. Elsevier 2023-08-25 /pmc/articles/PMC10481298/ /pubmed/37681156 http://dx.doi.org/10.1016/j.heliyon.2023.e19468 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Kundert, Danielle N. Tavassol, Frank Kampmann, Andreas Gellrich, Nils-Claudius Lindhorst, Daniel Precht, Marc M. Schumann, Paul Alendronate reduces periosteal microperfusion in vivo |
title | Alendronate reduces periosteal microperfusion in vivo |
title_full | Alendronate reduces periosteal microperfusion in vivo |
title_fullStr | Alendronate reduces periosteal microperfusion in vivo |
title_full_unstemmed | Alendronate reduces periosteal microperfusion in vivo |
title_short | Alendronate reduces periosteal microperfusion in vivo |
title_sort | alendronate reduces periosteal microperfusion in vivo |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481298/ https://www.ncbi.nlm.nih.gov/pubmed/37681156 http://dx.doi.org/10.1016/j.heliyon.2023.e19468 |
work_keys_str_mv | AT kundertdaniellen alendronatereducesperiostealmicroperfusioninvivo AT tavassolfrank alendronatereducesperiostealmicroperfusioninvivo AT kampmannandreas alendronatereducesperiostealmicroperfusioninvivo AT gellrichnilsclaudius alendronatereducesperiostealmicroperfusioninvivo AT lindhorstdaniel alendronatereducesperiostealmicroperfusioninvivo AT prechtmarcm alendronatereducesperiostealmicroperfusioninvivo AT schumannpaul alendronatereducesperiostealmicroperfusioninvivo |